HILS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (22 Sep 2023 @ 15:59):

Stats
Today's Volume	313 195
Average Volume	684 778
Market Cap	4.17M
EPS	$-0.105 ( 2023-11-13 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.339
ATR14	$0.0350 (19.34%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-15	Milby Randy	Buy	29 000	Common Stock
2023-11-30	Milby Randy	Buy	10 000	Common Stock
2023-11-07	Bui Lynne A.	Buy	25 000	Options (right to buy)
2023-11-07	Appajosyula Sireesh	Buy	25 000	Options (right to buy)
2023-11-07	Anderson Kelly	Buy	50 000	Options (right to buy)

INSIDER POWER
94.20
Last 99 transactions
Buy: 3 498 545 \| Sell: 667 792

Volume Correlation

Long: -0.01 (neutral)

Short: 0.08 (neutral)

Signal:(41.23) Neutral

Hillstream BioPharma, Correlation

10 Most Positive Correlations
MIGI	0.934
DRNA	0.926
RMRM	0.92
VYNE	0.916
NAOV	0.913
STX	0.913
OCSL	0.911
TREE	0.911
STTK	0.909
GALT	0.905

10 Most Negative Correlations
XPDI	-0.892
EAR	-0.885
BOCH	-0.885
DTSS	-0.884
NETE	-0.882
MMAC	-0.865
GMII	-0.865
FRTA	-0.854
AGIO	-0.849
BCYC	-0.845

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Hillstream BioPharma, Correlation - Currency/Commodity

-0.47
( neutral )

-0.12
( neutral )

0.00
( neutral )

0.63
( weak )

-0.32
( neutral )

0.05
( neutral )

Hillstream BioPharma, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-7.14

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.110

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.160

Q1	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.230

Financial Reports:

No articles found.

Hillstream BioPharma,

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.